These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 32613239)

  • 1. Validation Study of a German Cognitive Battery for Huntington's Disease: Relationship Between Cognitive Performance, Functional Decline, and Disease Burden.
    Mühlbäck A; Frank W; Klempířová O; Bezdíček O; Schmitt L; Hofstetter N; Landwehrmeyer GB; Klempíř J
    Arch Clin Neuropsychol; 2021 Jan; 36(1):74-86. PubMed ID: 32613239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington's disease.
    Bezdicek O; Majerova V; Novak M; Nikolai T; Ruzicka E; Roth J
    Appl Neuropsychol Adult; 2013; 20(1):33-40. PubMed ID: 23373682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ideomotor limb apraxia in Huntington's disease: a case-control study.
    Hödl AK; Hödl E; Otti DV; Herranhof B; Ille R; Bonelli RM
    J Neurol; 2008 Mar; 255(3):331-9. PubMed ID: 18305889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of the Parkinson's disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington's disease.
    Martinez-Horta S; Horta-Barba A; Perez-Perez J; Sampedro F; de Lucia N; De Michele G; Kehrer S; Priller J; Migliore S; Squitieri F; Castaldo A; Mariotti C; Mañanes V; Lopez-Sendon JL; Rodriguez N; Martinez-Descals A; Garcia-Ruiz P; Júlio F; Januário C; Delussi M; de Tommaso M; Noguera S; Ruiz-Idiago J; Sitek EJ; Nuzzi A; Pagonabarraga J; Kulisevsky J;
    J Neurol; 2020 May; 267(5):1527-1535. PubMed ID: 32030521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering Cognitive Impairments in Huntington's Disease: A Comparative Study of Stroop Test Variations.
    Sierra LA; Wynn A; Lanzaro E; Dzekon K; Russell A; Halko M; Claassen DO; Frank S; Considine CM; Laganiere S
    J Huntingtons Dis; 2024; 13(2):249-257. PubMed ID: 38759020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity, diagnostics and feasibility of the Italian version of the Montreal Cognitive Assessment (MoCA) in Huntington's disease.
    Aiello EN; Solca F; Torre S; Lafronza A; Maranzano A; Bonetti R; Scheveger F; Maffi S; Ceccarelli C; Scocchia M; Casella M; Verde F; Migliore S; Silani V; Ticozzi N; Squitieri F; Ciammola A; Poletti B
    Neurol Sci; 2024 Mar; 45(3):1079-1086. PubMed ID: 37770762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive and Motor Norms for Huntington's Disease.
    Mills JA; Long JD; Mohan A; Ware JJ; Sampaio C
    Arch Clin Neuropsychol; 2020 Aug; 35(6):671-682. PubMed ID: 32407458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring the functional impact of cognitive impairment in Huntington's disease.
    Horta-Barba A; Martínez-Horta S; Pérez-Pérez J; Sampedro F; Puig-Davi A; Pagonabarraga J; Kulisevsky J
    J Neurol; 2022 Jul; 269(7):3541-3549. PubMed ID: 35061089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive deficits predict poorer functional capacity in Huntington's disease: but what is being measured?
    Eddy CM; Rickards HE
    Neuropsychology; 2015 Mar; 29(2):268-73. PubMed ID: 25110931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3.
    Stout JC; Queller S; Baker KN; Cowlishaw S; Sampaio C; Fitzer-Attas C; Borowsky B;
    Mov Disord; 2014 Sep; 29(10):1281-8. PubMed ID: 25209258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation--a longitudinal follow-up study.
    Lemiere J; Decruyenaere M; Evers-Kiebooms G; Vandenbussche E; Dom R
    J Neurol; 2004 Aug; 251(8):935-42. PubMed ID: 15316797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive change in patients with Huntington disease on the Repeatable Battery for the Assessment of Neuropsychological Status.
    Beglinger LJ; Duff K; Allison J; Theriault D; O'Rourke JJ; Leserman A; Paulsen JS
    J Clin Exp Neuropsychol; 2010 Jul; 32(6):573-8. PubMed ID: 19882420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severity of cognitive impairment in juvenile and late-onset Huntington disease.
    Gómez-Tortosa E; del Barrio A; García Ruiz PJ; Pernaute RS; Benítez J; Barroso A; Jiménez FJ; García Yébenes J
    Arch Neurol; 1998 Jun; 55(6):835-43. PubMed ID: 9626775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing cognitive function in patients with Huntington's disease from China: A cross-sectional clinical study.
    Cheng YF; Liu KC; Yang TM; Xiao Y; Jiang QR; Huang JX; Zhang S; Wei QQ; Ou RW; Li CY; Gu XJ; Burgunder JM; Shang HF
    Brain Behav; 2023 Nov; 13(11):e3258. PubMed ID: 37849450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing normative data for the evaluation of cognitive performance in Huntington's disease considering the impact of gender, age, language, and education.
    Mühlbäck A; Mana J; Wallner M; Frank W; Lindenberg KS; Hoffmann R; Klempířová O; Klempíř J; Landwehrmeyer GB; Bezdicek O;
    J Neurol; 2023 Oct; 270(10):4903-4913. PubMed ID: 37347292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bradykinesia in early Huntington's disease.
    Sánchez-Pernaute R; Künig G; del Barrio Alba A; de Yébenes JG; Vontobel P; Leenders KL
    Neurology; 2000 Jan; 54(1):119-25. PubMed ID: 10636136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive performance in healthy clinical trial participants and patients with the NeuroCart, a neurodegenerative disease measured with an automated neuropsychological and neurophysiological test battery.
    Prins S; Borghans L; de Kam ML; Groeneveld GJ; van Gerven J
    J Neurol Sci; 2023 Jun; 449():120658. PubMed ID: 37079973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visual Object Perception in Premanifest and Early Manifest Huntington's Disease.
    Coppen EM; Jacobs M; van der Zwaan KF; Middelkoop HAM; Roos RAC
    Arch Clin Neuropsychol; 2019 Nov; 34(8):1320-1328. PubMed ID: 30796801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive Dysfunction Contributes to Mobility Impairments in Huntington's Disease.
    Kloos AD; Kegelmeyer DA; Fritz NE; Daley AM; Young GS; Kostyk SK
    J Huntingtons Dis; 2017; 6(4):363-370. PubMed ID: 29254103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive decline in Huntington's disease expansion gene carriers.
    Baake V; Reijntjes RHAM; Dumas EM; Thompson JC; ; Roos RAC
    Cortex; 2017 Oct; 95():51-62. PubMed ID: 28843844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.